As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Novo Nordisk was the leader in the space until Eli Lilly launched tirzepatide. The Denmark-based pharmaceutical giant markets ...

The demand for weight-loss drugs like Ozempic and Zepbound is higher than ever, so much so that drugmakers Novo Nordisk and Eli Lilly are planning huge expansions in central North Carolina to meet the ...

Eli Lilly has officially entered the elite $1 trillion market-value club, becoming the first pharmaceutical company to reach ...

The Indianapolis drug giant's stock (LLY) reached an intraday high of $1,061.17 in morning trading and closed at $1,059.70 on Friday, which was above the threshold of $1,057.78 needed for Lilly to ...

Eli Lilly has become the first healthcare company to hit a $1 trillion market value, entering an exclusive club dominated by ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

While Novo Nordisk and Pfizer intensify their plays, Lilly’s early lead in GLP-1 treatments has put it in a category all its ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...